Literature DB >> 31076292

Biosynthesis of nerol from glucose in the metabolic engineered Escherichia coli.

Zhen Zong1, Qingsong Hua1, Xinyu Tong1, Dongsheng Li1, Chao Wang1, Daoyi Guo2, Zhijie Liu3.   

Abstract

In this study, nerol was biosynthesized in the metabolic engineered Escherichia coli from glucose for the first time. Firstly, the truncated neryl diphosphate synthase gene tNDPS1 was expressed that catalyzes isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP) to form neryl diphosphate (NPP), and then the nerol synthase gene GmNES was co-expressed to synthesize the final product nerol from NPP. The engineered strain LZ001 accumulated 0.053 ± 0.015 mg/L of nerol. Secondly, the IDI1, MVD1, ERG8, ERG12, tHMG1 and ERG13 were co-expressed to increase the supply of IPP and DMAPP. Finally, the heterologous ERG10 gene was overexpressed, and the recombinant strain LZ005 produced 1.564 ± 0.102 mg/L of nerol in shaking-flask culture, which represents a 29.51-fold increase over LZ001 strain. This study shows the novel method for the biosynthesis of nerol and provides new metabolic engineering strategy for the production of terpenoids.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Escherichia coli; MVA pathway; Nerol; Neryl diphosphate

Mesh:

Substances:

Year:  2019        PMID: 31076292     DOI: 10.1016/j.biortech.2019.121410

Source DB:  PubMed          Journal:  Bioresour Technol        ISSN: 0960-8524            Impact factor:   9.642


  2 in total

Review 1.  Monoterpenoid biosynthesis by engineered microbes.

Authors:  Yurou Liu; Xiaoqiang Ma; Hong Liang; Gregory Stephanopoulos; Kang Zhou
Journal:  J Ind Microbiol Biotechnol       Date:  2021-12-23       Impact factor: 4.258

2.  Whole genome sequencing and metabolomics analyses reveal the biosynthesis of nerol in a multi-stress-tolerant Meyerozyma guilliermondii GXDK6.

Authors:  Xueyan Mo; Xinghua Cai; Qinyan Hui; Huijie Sun; Ran Yu; Ru Bu; Bing Yan; Qian Ou; Quanwen Li; Sheng He; Chengjian Jiang
Journal:  Microb Cell Fact       Date:  2021-01-03       Impact factor: 5.328

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.